Clinical Trial Update: A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of LX211 in active non-infectious anterior uveitis (including panuveitis) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anterior Uveitis
• Panuveitis

Drugs mentioned

• LX211

Snippet

Sponsor: Lux Biosciences, Inc. | Conditions: Uveitis, Anterior, Panuveitis | Phase 3 | Status: COMPLETED